Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

USC / Norris Comprehensive Cancer Center

USC / Norris Comprehensive Cancer Center in Los Angeles, California, United States is listed as a site for 942 registered clinical trials, 367 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 942
Ongoing 367

This page covers the site record USC / Norris Comprehensive Cancer Center in Los Angeles, California, United States: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled.

Get the USC / Norris Comprehensive Cancer Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 942 trials counted.

  • Phase 1 154 trials
  • Phase 1/2 104 trials
  • Phase 2 315 trials
  • Phase 2/3 26 trials
  • Phase 3 193 trials
  • Phase 4 3 trials
  • Not applicable 75 trials
  • Observational 68 trials
  • Expanded access 4 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 370 trials
  • Completed 347 trials
  • Terminated 207 trials
  • Other 18 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 64

1992: 1 trials (Phase 3 1) 1993: 2 trials (Phase 2 2) 1994: 8 trials (Phase 3 4, Phase 2 3, Phase 1/2 1) 1995: 5 trials (Observational 1, Phase 3 1, Phase 2 3) 1996: 8 trials (Phase 3 3, Phase 2 3, Phase 1 2) 1997: 13 trials (Observational 2, Phase 3 2, Phase 2 7, Phase 1/2 1, Phase 1 1) 1998: 22 trials (Phase 3 5, Phase 2 14, Phase 1 3) 1999: 14 trials (Phase 3 2, Phase 2 9, Phase 1/2 1, Phase 1 2) 2000: 15 trials (Phase 3 3, Phase 2 8, Phase 1 4) 2001: 1 trials (Phase 2 1) 2002: 3 trials (Not applicable 1, Phase 2 2) 2003: 5 trials (Phase 3 2, Phase 2 2, Phase 1 1) 2004: 8 trials (Phase 3 2, Phase 2 5, Phase 1/2 1) 2005: 9 trials (Not applicable 2, Phase 3 2, Phase 2 4, Phase 1/2 1) 2006: 13 trials (Not applicable 1, Phase 3 3, Phase 2 3, Phase 1/2 3, Phase 1 3) 2007: 10 trials (Not applicable 1, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 2) 2008: 21 trials (Observational 1, Not applicable 1, Phase 3 4, Phase 2 9, Phase 1/2 3, Phase 1 3) 2009: 27 trials (Observational 1, Not applicable 1, Phase 3 10, Phase 2 9, Phase 1/2 2, Phase 1 4) 2010: 33 trials (Not applicable 2, Phase 3 6, Phase 2 15, Phase 1/2 6, Phase 1 4) 2011: 32 trials (Observational 2, Not applicable 5, Phase 3 9, Phase 2 12, Phase 1/2 1, Phase 1 3) 2012: 42 trials (Not applicable 4, Phase 3 4, Phase 2/3 1, Phase 2 17, Phase 1/2 4, Phase 1 12) 2013: 36 trials (Observational 1, Not applicable 4, Phase 3 7, Phase 2 13, Phase 1/2 3, Phase 1 8) 2014: 43 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 5, Phase 2/3 8, Phase 2 9, Phase 1/2 3, Phase 1 5) 2015: 45 trials (Observational 5, Not applicable 4, Phase 3 11, Phase 2/3 2, Phase 2 15, Phase 1/2 4, Phase 1 4) 2016: 46 trials (Observational 9, Not applicable 5, Phase 3 6, Phase 2 14, Phase 1/2 4, Phase 1 8) 2017: 64 trials (Observational 7, Not applicable 9, Phase 3 14, Phase 2/3 1, Phase 2 24, Phase 1/2 3, Phase 1 6) 2018: 44 trials (Observational 4, Not applicable 1, Phase 3 9, Phase 2 14, Phase 1/2 9, Phase 1 7) 2019: 49 trials (Observational 1, Not applicable 8, Phase 4 1, Phase 3 11, Phase 2/3 3, Phase 2 10, Phase 1/2 7, Phase 1 8) 2020: 48 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 10, Phase 2 14, Phase 1/2 7, Phase 1 9) 2021: 50 trials (Observational 3, Not applicable 3, Phase 3 10, Phase 2/3 1, Phase 2 10, Phase 1/2 13, Phase 1 10) 2022: 50 trials (Observational 6, Not applicable 3, Phase 3 3, Phase 2/3 2, Phase 2 21, Phase 1/2 6, Phase 1 9) 2023: 54 trials (Observational 4, Not applicable 7, Phase 3 10, Phase 2 10, Phase 1/2 9, Phase 1 14) 2024: 45 trials (Observational 4, Not applicable 3, Phase 3 13, Phase 2/3 2, Phase 2 9, Phase 1/2 4, Phase 1 10) 2025: 42 trials (Observational 3, Not applicable 1, Phase 3 12, Phase 2/3 3, Phase 2 10, Phase 1/2 6, Phase 1 7)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 28
2025 42
2024 45
2023 54
2022 50
2021 50
2020 48
2019 49
2018 44
2017 64

2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Conditions studied

The specific conditions of the trials that list this site, most trials first.